Osmosis Investment Management UK Ltd Has $10.42 Million Position in Waters Corporation $WAT

Osmosis Investment Management UK Ltd decreased its holdings in shares of Waters Corporation (NYSE:WAT) by 52.5% during the 2nd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 27,778 shares of the medical instruments supplier’s stock after selling 30,757 shares during the quarter. Osmosis Investment Management UK Ltd’s holdings in Waters were worth $10,418,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also modified their holdings of the company. Anchor Investment Management LLC bought a new position in Waters in the 1st quarter worth $27,000. Resources Management Corp CT ADV bought a new stake in Waters during the first quarter valued at about $27,000. Zions Bancorporation National Association UT boosted its holdings in Waters by 121.2% during the fourth quarter. Zions Bancorporation National Association UT now owns 73 shares of the medical instruments supplier’s stock valued at $28,000 after acquiring an additional 40 shares during the period. Vision Retirement LLC acquired a new stake in shares of Waters in the first quarter valued at about $29,000. Finally, Bollard Group LLC bought a new position in shares of Waters in the first quarter worth about $29,000. Institutional investors own 94.01% of the company’s stock.

Insider Activity

In other Waters news, Director Christopher A. Kuebler sold 3,626 shares of Waters stock in a transaction that occurred on Thursday, August 6th. The shares were sold at an average price of $397.94, for a total value of $1,442,930.44. Following the transaction, the director owned 17,808 shares of the company’s stock, valued at approximately $7,086,515.52. The trade was a 16.92% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. 0.31% of the stock is owned by company insiders.

Waters Stock Up 0.4%

NYSE:WAT opened at $412.37 on Monday. The company has a market cap of $40.52 billion, a price-to-earnings ratio of 102.84, a P/E/G ratio of 2.39 and a beta of 1.19. The company has a debt-to-equity ratio of 0.32, a quick ratio of 1.29 and a current ratio of 1.86. The stock’s fifty day moving average price is $381.79 and its two-hundred day moving average price is $347.02. Waters Corporation has a 52-week low of $282.77 and a 52-week high of $421.74.

Waters (NYSE:WAT) last issued its earnings results on Tuesday, August 4th. The medical instruments supplier reported $3.05 earnings per share (EPS) for the quarter, beating the consensus estimate of $3.01 by $0.04. Waters had a net margin of 3.58% and a return on equity of 11.27%. The company had revenue of $1.65 billion for the quarter, compared to analyst estimates of $1.62 billion. During the same quarter last year, the firm earned $2.95 EPS. The company’s revenue for the quarter was up 113.3% on a year-over-year basis. Waters has set its Q3 2026 guidance at 3.950-4.050 EPS and its FY 2026 guidance at 14.450-14.650 EPS. On average, analysts anticipate that Waters Corporation will post 14.57 EPS for the current year.

Wall Street Analyst Weigh In

Several equities research analysts have recently weighed in on the company. JPMorgan Chase & Co. increased their price objective on Waters from $330.00 to $345.00 and gave the company a “neutral” rating in a research report on Wednesday, May 6th. Bank of America boosted their target price on shares of Waters from $370.00 to $400.00 and gave the stock a “neutral” rating in a research report on Tuesday, June 2nd. Deutsche Bank Aktiengesellschaft reiterated a “hold” rating and set a $400.00 target price on shares of Waters in a research note on Wednesday, August 5th. The Goldman Sachs Group increased their price target on shares of Waters from $380.00 to $425.00 and gave the company a “buy” rating in a report on Tuesday, July 14th. Finally, Wells Fargo & Company raised their price target on shares of Waters from $370.00 to $400.00 and gave the stock an “equal weight” rating in a research report on Wednesday, August 5th. Three equities research analysts have rated the stock with a Strong Buy rating, nine have issued a Buy rating and eight have given a Hold rating to the company. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $420.35.

About Waters

Waters Corporation is a global provider of analytical instruments, software and services for laboratory and research applications. The company designs, manufactures and sells technologies centered on liquid chromatography, mass spectrometry, separation science, and related sample preparation and detection systems. Its product portfolio includes chromatographs, mass spectrometers, columns and consumables, laboratory informatics and workflow software, as well as technical support and training services that help customers run and interpret complex analyses.

Waters serves a wide range of end markets that include pharmaceutical and biotechnology companies, contract research and testing laboratories, academic and government research institutions, clinical diagnostics, food and environmental testing, and industrial and chemical manufacturers.